Quantcast

Latest Transition Therapeutics Inc. Stories

2009-06-18 12:30:00

TORONTO, June 18 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), is pleased to announce that Ms. Laura Agensky has been appointed Vice-President of Clinical Operations. Since joining Transition in 2001, Ms. Agensky has managed the execution of all the Company's clinical trials across a diverse set of disease indications including Alzheimer's disease and diabetes. Prior to Transition, she served in multiple clinical development...

2009-05-13 15:01:00

TORONTO, May 13 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2009. Selected Highlights ------------------- During the third quarter of fiscal 2009 and up to the date of this press release, the Company achieved the following...

2009-05-12 09:00:00

TORONTO, May 12 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, May 13, 2009 at 4:30 P.M. EST to discuss the Third Quarter fiscal 2009 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the...

2009-03-23 06:01:00

TORONTO, March 23 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ:TTHI, TSX:TTH) announced today that the first patient has been dosed in a clinical study of gastrin analogue TT-223 in combination with a proprietary Lilly GLP-1 analogue, in patients with type 2 diabetes. The study is a randomized, double-blind, placebo-controlled study in approximately 140 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in...

2009-02-11 15:01:00

TORONTO, Feb. 11 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2008. Selected Highlights ------------------- During the second quarter of fiscal 2009 and up to the date of this press release, the Company achieved the following...

2009-02-05 06:30:00

TORONTO, Feb. 5 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH, NASDAQ:TTHI) today announced the completion of patient enrolment for a Phase 2 clinical study of gastrin analogue, TT-223, in patients with type 2 diabetes. The study is a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability and efficacy of daily TT-223 treatments for 12 weeks with a 6-month follow-up. Approximately 80 patients with...

2008-12-01 09:45:00

TORONTO, Dec. 1 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH, NASDAQ:TTHI) today announced the dates for the following upcoming corporate events: 20th Annual Piper Jaffray Health Care Conference Transition will present at the upcoming 20th Annual Piper Jaffray Health Care Conference. The presentation will take place on Tuesday, December 2nd, 2008 at 12:30 P.M. (Eastern Time) at the New York Palace. 2008 Annual General Meeting of...

2008-10-20 03:00:08

Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) today announced the achievement of the patient enrollment target for a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in patients with mild to moderate Alzheimer's disease. Each patient's planned treatment period is approximately 18 months. About ELND005 (AZD-103)...

2008-09-12 06:00:34

TORONTO, Sept. 12 /PRNewswire-FirstCall/ -- Transition Therapeutics Inc. ("Transition" or the "Company") today announced that the first patient has been dosed in a Phase 2 clinical study of gastrin analogue, TT-223, in patients with type 2 diabetes. The study is a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability and efficacy of daily TT-223 treatments for 12 weeks with a 6-month follow-up. Approximately 80 patients with type 2 diabetes...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related